On 4/19/2017, Shares of ResMed Inc. (NYSE:RMD) closed at $69.10 in last trading day. After noting the initial trading entry at $69.01, it reached to a day’s high of $69.17 and moved to a day’s low of $68.58. The recent daily volume was 473.62 thousand as contrast to it’s an average volume of 767.98 thousand.
The last close of the ResMed Inc. stock reflects that it traded -2.41% from its 50-day moving average of $70.81. The stock traded above +5.48% to its 200-day MA of $65.51. Furthermore, it moved lower -5.94% from its 52-week high of $73.46 and +24.66% up from $55.43, which is 52-week low of the stock.
During the last month, ResMed Inc.’s (RMD) has changed -3.10% and performed 8.81% over the last 6 months. The mean rating score for this stock is at 2.80. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 1.38% in recent month and observed Weekly Volatility of 1.21%.
ResMed Inc. designs, develops, manufactures, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders. Its portfolio of products include devices, such as air flow generators, ventilators, and oxygen concentrators; diagnostic products; mask systems; headgear and other accessories; dental devices; portable oxygen concentrators; and cloud-based software informatics solutions. The company also produces continuous positive airway pressure, variable positive airway pressure, and AutoSet systems for the titration and treatment of sleep disordered breathing (SDB). In addition, it offers data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 100 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Seattle Genetics, Inc. (NASDAQ:SGEN) finalized the last transaction at value of $66.565, with a daily change of -0.128% or -0.085 points. The company maintained volume of 446.46 thousand shares. In past trading day, the stock hit the maximum price of $67.360 and touched to minimum value of $65.970. It has a market cap of $ 9.49B.
As of last trade close, the stock is trading downside -11.671% from its one year high of $75.360 and moved +105.479% upward from $32.395, which is one year low of the stock.
The stock traded above +1.733% from its 50-day moving average of $65.431. Furthermore, the stock moved up +8.184% to its 200-day MA of $ 61.529.
Seattle Genetics, Inc.’s (SGEN) moved with shift of 4.93% in the past week. Over the last three months, the shares of the company have changed 12.75% and performed 32.76% over the last six months. The stock currently has Monthly Volatility of 3.20% and Weekly Volatility of 2.74%.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML); ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with relapsed DLBCL. In addition, it is involved developing SEA-CD40 that is in Phase I clinical trial for patients with solid tumors and hematologic malignancies; SGN-CD19B, which is in Phase I clinical trial ongoing for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; SGN-CD123A that is in Phase I trial for patients with relapsed or refractory AML; SGN-CD352A, which is in Phase I clinical trial for patients with relapsed or refractory multiple myeloma; SGN-2FF that is in Phase I clinical trial for patients with advanced solid tumors; and ASG-15ME that is in Phase I clinical trial for patients with urothelial cancer. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; and Unum Therapeutics, Inc., as well as has co-development agreement with Agensys, Inc. and Genmab A/S. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.